Main Article Content
Public reimbursement, off lable, prescription drugs
Author's response to comments from Dr Lexchin's Letter to the Editor regarding our article.
2. Canadian Agency for Drugs and Technologies in Health. Anti-vascular endothelial growth factor (VEGF) drugs for the treatment of retinal conditions: recommendations report (May 2016). https://www.cadth.ca/sites/default/files/pdf/TR0009_Anti-VEGFs_Recs_Report.pdf (accessed on: November 20, 2018).
3. Lexchin J. Editorial. J Popul Ther Clin Pharmacol 2018;25:e31-2.
4. Avastin Product Monograph (June 6, 2018). http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Avastin/Avastin_PM_E.pdf (accessed on: November 20, 2018).
5. Rawson NSB, Adams J. Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles? Clinicoecon Outcomes Res 2017;9:721–30.